CD4 and melanoma: Two years later, the same group and Catherine Wu’s group published back-to-back reports reporting clinical findings showing that personalised neoantigen vaccines for melanoma patients primarily induced tumour-specific responses in CD4+ rather than CD8+ T cells [39, 40].